Thiogenesis Therapeutics, Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is developing sulfur-containing prodrugs that act as precursors with the potential to treat serious pediatric diseases with unmet medical needs. Its lead compound, TTI-0102, is a disulfide, made up of two thiols that lead to two independent cysteamine molecules. Cysteamine is a thiol that has been rigorously studied and tested. TTI-0102 has been developed to address the obstacles facing previous thiol-based drugs, their short half-lives and side effects. As a prodrug, TTI-0102 is metabolized into cysteamine molecules after it is ingested. The metabolic process acts as a gating mechanism that eliminates the spike in the immediate release of cysteamine that is commonly linked to GI side effects. TTI-0102â€™s initial applications are for mitochondrial encephalopathy, lactic acidosis and stroke-like episodes, Leigh syndrome, Rett syndrome and pediatric Nonalcoholic steatohepatitis.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
20/26/20	CA$0.5000	-9.09%	2,05,666
19/26/19	CA$0.5500	0.00%	50,500
14/26/14	CA$0.5500	-3.51%	13,000
13/26/13	CA$0.5700	+3.64%	28,000

Delayed Quote Toronto S.E.

More quotes

Net sales - Rate of surprise

Company calendar

Delayed Toronto S.E. 07:00:00 20/08/2026 pm IST			5-day change	1st Jan Change
0.5000 ^CAD	-9.09%		-12.28%	-23.08%

07/08	Thiogenesis Therapeutics, Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
13/07	Thiogenesis Therapeutics Receives Fda Rare Pediatric Disease Designation for Tti-0102 for the Treatment of Leigh Syndrome	CI

Market Cap	3.85Cr 2.79Cr 2.39Cr 2.23Cr 2.05Cr 267.37Cr 3.92Cr 26Cr 10Cr 134Cr 10Cr 10Cr 443.62Cr	P/E 2024	-8.65x	P/E 2025	-4.25x
Enterprise Value	3.69Cr 2.68Cr 2.29Cr 2.14Cr 1.96Cr 256.15Cr 3.76Cr 25Cr 9.89Cr 128.37Cr 10Cr 9.83Cr 424.99Cr	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	87.27%	Yield 2024 *	-	Yield 2025	-

07/08	Thiogenesis Therapeutics, Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
13/07	Thiogenesis Therapeutics Receives Fda Rare Pediatric Disease Designation for Tti-0102 for the Treatment of Leigh Syndrome	CI
13/07	Thiogenesis Therapeutics' Treatment For Leigh Syndrome Receives FDA Rare Pediatric Disease Designation	MT
17/06	Thiogenesis Therapeutics Appoints Gilad Aharon to its Board	MT
17/06	Thiogenesis Therapeutics, Corp. Appoints Gilad Aharon to Its Board of Directors	CI
03/06	Thiogenesis Therapeutics, Corp. announced that it has received CAD 9.07185 million in funding	CI
26/05	Thiogenesis Therapeutics, Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
11/05	Thiogenesis Therapeutics to Raise $8 Million Via a Non-Brokered Private Placement	MT
11/05	Thiogenesis Therapeutics, Corp. announced that it expects to receive CAD 8 million in funding	CI
01/05	Thiogenesis Therapeutics, Corp. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
30/04	Thiogenesis Therapeutics, Corp. Auditor Raises 'Going Concern' Doubt	CI
02/02	Thiogenesis Therapeutics, Corp. Provides Program Update	CI
23/01	Thiogenesis Therapeutics, Corp. Announces the Presentation of Interim Data from Its Phase 2 (Eu) Clinical Study of Tti-0102 in Patients with Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes At Mitocon 2026	CI

13/07	Thiogenesis Receives FDA Rare Pediatric Disease Designation for TTI-0102 for the Treatment of Leigh Syndrome	NE
17/06	Thiogenesis Appoints Dr. Gilad Aharon to Its Board of Directors	NE
03/06	Thiogenesis Closes Oversubscribed Non-Brokered Private Placement for Gross Proceeds of C$9.07 Million	NE
02/06	Thiogenesis Upsizes Non-Brokered Private Placement of Common Shares	NE
11/05	Thiogenesis Announces Non-Brokered Private Placement	NE

Thiogenesis Therapeutics, Corp. Share Price

Stocks

TTI

CA88410L1022

Biotechnology & Medical Research

Valuation: Thiogenesis Therapeutics, Corp.

Chart: Thiogenesis Therapeutics, Corp.

Latest news : Thiogenesis Therapeutics, Corp.

Analysts' recommendations: Thiogenesis Therapeutics, Corp.

Press Releases: Thiogenesis Therapeutics, Corp.

Quotes and Performance

Course Extremes

Managers and Directors: Thiogenesis Therapeutics, Corp.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Net sales - Rate of surprise

1 day	-9.09%
1 week	-12.28%
Current month	-7.41%
1 month	-9.09%
3 months	-10.71%
6 months	-9.09%
Current year	-23.08%

1 week	0.5	0.58
1 month	0.5	0.58
Current year	0.44	0.66
1 year	0.44	0.82
3 years	0.44	1.06
5 years	0.38	1.06
10 years	0.38	1.06

Manager	Title	Age	Since
Patrice Rioux CEO	Chief Executive Officer	75	31/03/2022
Brook Riggins CEO	Chief Executive Officer	60	-

Director	Title	Age	Since
Christopher Starr CHM	Chairman	73	31/03/2022
Patrice Rioux BRD	Director/Board Member	75	31/03/2022
Brook Riggins BRD	Director/Board Member	60	03/05/2018

Date	Insider	Type	Main position	Quantity	% Market Cap.
11/09/25	W. Mullally	Option	Director	75,000	0.1702%
01/08/25	W. Mullally	Sell	Director	64,000	0.1453%
12/06/25	Christopher Starr	Option	Chairman	2,00,000	0.4540%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
THIOGENESIS THERAPEUTICS, CORP.	-9.09%	-12.28%	-37.50%	-23.08%	2.79Cr
LONZA GROUP AG	+1.14%	+2.27%	+2.38%	+24.66%	5.05TCr
REVOLUTION MEDICINES, INC.	-1.64%	+4.68%	+484.76%	+607.90%	4.6TCr
BEONE MEDICINES AG	-1.22%	+4.60%	+20.39%	+89.88%	4.28TCr
IQVIA HOLDINGS INC.	+3.99%	+7.13%	+34.73%	+20.71%	4.1TCr
CELLTRION, INC.	0.00%	-3.91%	+17.87%	+47.98%	3.2TCr
MEDPACE HOLDINGS, INC.	+1.70%	+6.13%	+32.62%	+151.09%	1.7TCr
ASCENDIS PHARMA A/S	-1.45%	+4.05%	-	-	1.71TCr
EUROFINS SCIENTIFIC SE	+3.06%	+3.88%	+5.81%	+35.45%	1.43TCr
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+2.83%	+5.25%	+85.52%	+47.35%	1.38TCr
Average	-0.04%	+2.35%	+71.84%	+111.33%	2.75TCr
Weighted average by Cap.	+0.70%	+2.37%	+105.27%	+152.11%

	2024	2025
Net sales	-	-
Net income	-31.46L -22.84L -19.55L -18.24L -16.74L -22Cr -32.08L -2.16Cr -84.37L -11Cr -85.75L -83.89L -36Cr	-74.26L -53.91L -46.16L -43.07L -39.52L -52Cr -75.72L -5.11Cr -1.99Cr -26Cr -2.02Cr -1.98Cr -86Cr
Net Debt	-38.48L -27.94L -23.92L -22.32L -20.48L -27Cr -39.24L -2.65Cr -1.03Cr -13Cr -1.05Cr -1.03Cr -44Cr	-16.16L -11.73L -10.05L -9L -9L -11Cr -16.48L -1.11Cr -43.34L -5.63Cr -44.05L -43.09L -19Cr